Adjuvant activity can be greatly improved by appropriate formulation of cytosine-phosphorothioate-guanine oligodeoxynucleotides (CpG ODNs).
Paul Colussi
Advertisement
Paul Colussi is the head of protein expression at Tetragenetics Inc
Articles by Paul Colussi
Advertisement
Latest Updated Articles
An Alternative Platform for Rapid Production of Effective Subunit VaccinesPublished: October 2nd 2010 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Regulatory Challenges for Global Manufacturing of Vaccines
2
AI-Driven Organ-on-Chip Platforms Are Changing the Game in Bio/Pharma R&D
3
EU Biopharma Strategy: Scaling Up to Tackle Funding Gaps and Drive Innovation
4
Executive Summary: Charge Detection Mass Spectrometry (CDMS): From Complexity to Clarity – A New Era in Biomolecular Analysis
5
